Prescription Drug Monitoring Programs (PDMPs): An Important Tool to Decrease Diversion and Abuse of Opioids

Prescription Drug Monitoring Programs (PDMPs), or Prescription Monitoring Programs (PMPs), are electronic databases that track the dispensing of controlled substances, including opioids. PDMPs have been shown to not only decrease diversion and doctor shopping and favorably impact prescribing habits, but also to improve patient safety. Nonetheless, the use of these programs is very low. While there is a great deal of variability from state to state in terms of the type of information and the timeliness with which the information can be obtained from the PDMP, active participation in these programs by the prescribers contributes to appropriate prescribing of controlled substances. Consequently, use of PDMPs is an important component of the public health approaches to reduce prescription opioid misuse.

There are two Webinars in the series “Prescription Drug Monitoring Programs: An Important Tool to Decrease Diversion and Abuse of Opioids.” Webinar A focuses on guarding against drug diversion whilst Webinar B discusses valuable clinical tools in treating pain and substance use disorders.

TARGET AUDIENCE 

This activity is intended for healthcare professionals who treat patients with pain.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Evaluate the importance of participation in their state's Prescription Drug Monitoring Program
  2. Differentiate among addiction, tolerance, and physical dependence
  3. Identify clinical scenarios in which the discontinuation of opioid therapy is indicated

Faculty

John T. Finnell, MD, MSc

Research Scientist
Regenstrief Institute, Inc.
Associate Professor of Clinical Emergency Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Bob Twillman, PhD, FAPM
Executive Director
American Academy of Pain Management

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty                                  

Relationship Identified With:

John T. Finnell, MD, MSc

Nothing to disclose with regard to commercial interests

Bob Twillman, PhD, FAPM

Consultant: Janssen Pharmaceuticals, Zogenix
Speakers Bureau: Janssen Pharmaceuticals

Planners, Managers, and Reviewers: Sandy Breslow; Brynne Hunter; Lyerka Miller, PhD; Melanie Spurgeon; Jan Schultz; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months. 

Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education (EOCME) and Miller Medical Communications, LLC. The EOCME is accredited to provide continuing medical education for physicians.

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Financial Support

This activity has been supported by educational grants from Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Zogenix, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Zogenix, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
06/30/2015
Course expires: 
06/29/2016
Rating: 
5

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
06/30/2015
Course expires: 
06/29/2016
Please login or register to take this course.